ArticleGlycoconjugate journal2007
Inhibition of galectin-3 mediated cellular interactions by pectic polysaccharides from dietary sources.
Article in Glycoconjugate journal, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 113 citations in OpenAlex.
- Plasmonic glyco-nanoparticles for single-test multiplexed detection and differentiation of cancer cells.Nanoscale · 2026Article
- Pleiotropic Effects of Modified Citrus Pectin.Nutrients · 2019Review
- Pectin and Pectin-Based Composite Materials: Beyond Food Texture.Molecules (Basel, Switzerland) · 2018Review
- The roles and mechanisms of homogalacturonan and rhamnogalacturonan I pectins on the inhibition of cell migration.International journal of biological macromolecules · 2018Article
- Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update.Theranostics · 2018Review
- The Role of Galectins as Modulators of Metabolism and Inflammation.Mediators of inflammation · 2018Review
- Ripening-induced chemical modifications of papaya pectin inhibit cancer cell proliferation.Scientific reports · 2017Article
- Novel polysaccharide binding to the N-terminal tail of galectin-3 is likely modulated by proline isomerization.Glycobiology · 2017Article
- Structural Characterization of a Rhamnogalacturonan I Domain from Ginseng and Its Inhibitory Effect on Galectin-3.Molecules (Basel, Switzerland) · 2017Article
- Antimetastatic pectic polysaccharide from Decalepis hamiltonii; galectin-3 inhibition and immune-modulation.Clinical & experimental metastasis · 2017Article
- Low or No Inhibitory Potency of the Canonical Galectin Carbohydrate-binding Site by Pectins and Galactomannans.The Journal of biological chemistry · 2016Article
- The inhibitory effects of a rhamnogalacturonan I (RG-I) domain from ginseng pectin on galectin-3 and its structure-activity relationship.The Journal of biological chemistry · 2013Article
- Anti-cancer activities of pH- or heat-modified pectin.Frontiers in pharmacology · 2013Review
- Analysis of the neutral polysaccharide fraction of MCP and its inhibitory activity on galectin-3.Glycoconjugate journal · 2012Article
- Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury.PloS one · 2011Article
- Modified citrus pectin anti-metastatic properties: one bullet, multiple targets.Carbohydrate research · 2009Review
- The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin-glycan interactions at the cell surface.The Biochemical journal · 2009Article
- Galectin-3 in urine of cancer patients: stage and tissue specificity.Journal of cancer research and clinical oncology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pectic polysaccharides from dietary sources such as Decalepis hamiltonii--swallow root (SRPP), Hemidesmus indicus (HPP), Nigella sativa--black cumin (BCPP), Andrographis serpyllifolia-(APP), Zingiber officinale--ginger (GRPP) and, citrus pectin (CPP) were examined for galectin inhibitory activity. Inhibition of (a) galectin-3 of MDA-MB-231 cells induced hemagglutination of red blood cells; (b) galectin-3 mediated interaction between normal/metastatic human buccal cells (NBC)/(MBC) and; (c) invasion of MDA-MB-231 and MBC in the invasive chamber was assessed. Results indicated that SRPP inhibited hemagglutination at Minimum Inhibitory Concentration (MIC) of 1.86 microg ml(-1) equivalent of carbohydrate as apposed to those of BCPP (130 microg ml(-1)), APP (40 microg ml(-1)), HPP (40 microg ml(-1)) and CPP (25 microg ml(-1)). GRPP even at concentration >1-6 mg ml(-1) did not inhibit agglutination. Also SRPP showed approximately 15 and 2 fold potent anti hemagglutination activity relative to that of galectin-3 specific sugars-galactose (MIC-27.1 microg ml(-1)) and lactose (MIC-4.16 microg ml(-1)) respectively. Further, SRPP at 10 microg ml(-1) inhibited agglutination of NBC by galectin-3 of MDA-MB-231 cells. Modified swallow root pectic polysaccharide (MSRPP) of 50 kDa retained anti hemagglutination activity (MIC of 1.03 microg ml(-1)) and inhibited MDA-MB-231 and MBC invasion by 73 and 50% with an IC(50) of 136 and 200 microg ml(-1) respectively. Both SRPP and MSRPP induced apoptosis up to 80% at 100 microg ml(-1) concentration by activating approximately 2 and 8 folds of Caspase-3 activity. Sugar composition analysis and its correlation with the galectin inhibitory property indicated that pectic polysaccharides with higher arabinose and galactose content-arabinogalactan inhibited hemagglutination significantly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.